CLAIRIgene selected to present at AAIC. To view the poster click below Jul 2023https://alz.confex.com/alz/2023/meetingapp.cgi/Paper/80698
CLAIRIgene featured in MedicalNewsToday Jul 2023https://www.medicalnewstoday.com/amp/articles/could-crispr-gene-therapy-help-treat-alzheimers-disease
CLAIRIgene featured by STAT News Jul 2023Researchers turn to CRISPR to unlock one of the trickiest diseases to treat:...
CLAIRIgene’s Alzheimer’s program received its first STTR award from the National Institute on Aging of the National Institutes of Health for the project entitled, “APOE-targeted therapy for precision medicine in late onset Alzheimer’s disease: A novel epigenome editing approach for downregulation of APOEe4 expression” Aug 2022
Dr. Kantor discussed CLAIRIgene’s APOE-targeted epigenome therapy for Alzheimer’s in an interview for VJDementia as part of the journal series for AAIC 2022. Aug 2022Click at the link Developing APOE targeted epigenome therapy for the treatment of Alzheimers Disease to listen to the interview.
Dr. Chiba-Falek participated as a panelist in the Alzheimer’s Association Business Consortium (AABC) Panel at the AAIC 2022 for a discussion on Therapeutic targets & strategies in Alzheimer’s disease Jul 2022
CLAIRIgene welcome Dr. Hamm to the leadership team to lead the business development of the company. Jun 2022
Dr. Chiba-Falek joined Susan Ryan, a senior director at The Green House Project, to the episode “Editing the genetics of Alzheimer’s” in the podcast series “Elevate Eldercare” to discuss her groundbreaking work, and what it could eventually mean for families and caregivers. Feb 2022Click at the link, to listen to the podcast broadcasted on February 9, 2022 Green House Podcast: Elevate Eldercare – Green House Project (thegreenhouseproject.org)
CLAIRIgene was awarded a SRA from Seelos Therapeutics for a research project entitled: “Neuronal-type specific gene therapy for dementia with Lewy Body” Aug 2021
CLAIRIgene was awarded a SRA from Seelos Therapeutics for a research project entitled: “Modeling of neurodegenerative diseases via an all-in-one bimodal lentiviral vector” Jun 2020
